Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p.

Business Wire • Nov 25, 2025

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025. “During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rocket's AAV cardiovascular gene therapy portfolio,” said Gaurav Sha.

Business Wire • Nov 6, 2025

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Rocket (RCKT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Rocket securities between February 27, 2025 to May 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

GlobeNewsWire • Oct 23, 2025

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.

Zacks Investment Research • Oct 15, 2025

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I).

Benzinga • Oct 14, 2025

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte.

Business Wire • Oct 14, 2025

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that on October 6, 2025, the Compensation Committee of Rocket's Board of Directors approved the grant of inducement equity incentive awards to its newly-hired Chief Medical Officer, Dr. Syed Rizvi. The inducement awards consist of (i) a nonstatutory stock o.

Business Wire • Oct 10, 2025

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder.

Reuters • Oct 3, 2025

Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) breached their fiduciary duties to shareholders.

PRNewsWire • Sep 19, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Gaurav Shah - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

Seeking Alpha • Sep 9, 2025